Skip to content
Cartherics – The future of cancer treatment : off-the-shelf cellular immunotherapy for cancer. Logo Cartherics – The future of cancer treatment : off-the-shelf cellular immunotherapy for cancer. Logo Cartherics – The future of cancer treatment : off-the-shelf cellular immunotherapy for cancer. Logo
  • Home
  • Our Vision & Our Mission
  • Our Team
    • Board Members & Key Executives
    • Key Consultants
    • Scientific Advisory Board
    • Scientists
    • Current students
    • Past students
    • Office / Administration
    • Clinical & Regulatory Staff and Consultants
  • Cartherics News
  • Publications and Presentations
  • Our Technologies
    • Chimeric Antigen Receptor Technology
    • Cancer and the immune system
    • Our Lab
  • Join us
    • Investors
    • New Positions/ Recruitment – Closed
    • Education Opportunities
  • Contact Us

Publications and Presentations

Home > Publications and Presentations
Publications and Presentationscarth_admin2022-06-21T10:58:37+10:00

Integrin-Linked Kinase Expression Characterizes the Immunosuppressive Tumor Microenvironment in Colorectal Cancer and Regulates PD-L1 Expression and Immune Cell Cytotoxicity

Integrin-linked kinase (ILK) has been implicated as a molecular driver and mediator in both inflammation and tumorigenesis of the colon. However, a role for ILK in the tumor microenvironment (TME) and immune evasion has not been investigated. Here, we show a correlation of ILK expression with the immunosuppressive TME and cancer prognosis. We also uncover a role for ILK in the regulation of programmed death-ligand 1 (PD-L1) expression and immune cell cytotoxicity.

Read more

Presentation at the Locust Walk Stem Cell Tx Conference

Dr Ian Nisbet Chief Operating Officer

Held in partnership with Harvard Stem Cell Institute, this virtual one-day investor and partner conference will explore stem cell therapeutics in the areas of regenerative medicine, oncology and emerging academic research. It will also showcase cutting-edge science, industry trends and the commercial potential of this innovative sector to an invited group of 65 life science investors.

Company participation in the conference is by invitation only.  On Tuesday 12 April at 4:40 am AEST Ian will provide a non-confidential overview of Cartherics, its technology, lead product and pipeline, competitive position and more.

Webcast link

Download program

Presentation: 7th Innate Killer Summit (San Diego, California)

Cartherics Chief Development Officer, Dr Nicholas Boyd

The innate cell therapy field is exploding as novel research charges through the clinic, proving its potential as a safe, efficacious, and cost-effective treatment. From 30 March-1 April 2022 Pacific Daylight Time (PDT) industry experts will meet in San Diego, California to discuss the clinical and phase development of NK, Macrophage, γδT and NKT cell therapies for liquid and solid tumors.

On opening day Nicholas will make a presentation entitled “Optimizing Manufacturing Processes for iPSC-derived Cell Therapy Products”. On Friday PDT he will participate in a panel with representatives from Adicet Bio and Cellularity. They will discuss the complexity of identifying ‘optimal’ donors for off-the-shelf therapies.

View summit page

Presentation at the Next Generation CAR-TCR Summit (London, UK)

Cartherics Chief Development Officer, Dr Nicholas Boyd

CAR-T immunotherapy has exploded over the last half a decade. It is now a billion-dollar market that is expanding rapidly with over 400+ new cell therapy trials in 2021 alone. But challenges still remain in solid tumours, toxicity management and manufacturing innovations. Stakeholders across oncology and beyond are now turning to next-generation developments and technology to create the therapies of tomorrow, NOW!

This week Stakeholders are meeting at the Next Generation CAR-TCR Summit in London, UK. On Friday 25 February at 2:45 am AEDT – in a presentation entitled Allogeneic Solid Tumor Immunotherapy using iPSC-Derived Gene-Edited iNK Cells, Nicholas will discuss why the design, manufacture, delivery and cost of Cartherics’ allogeneic ‘off-the-shelf’ approach is superior to patient-derived allogeneic cell therapies.

View summit page

Presentation: Multi-Functional Cell Therapies Summit

Chief Development Officer, Dr Nicholas Boyd

Cell therapies have the potential to not only be life-saving but curative for a host of diseases. However, inherent limitations in autologous based CAR-T therapy face major roadblocks for mass adoption and therapeutic effects in solid tumour indications.

On Friday 28 January at 7:30 am AEDT Nicholas will discuss the design, manufacture and translation of cell therapies in a presentation entitled Advancing Off-The-Shelf Immunotherapy for Solid Tumours: Using Gene-Edited iNK Cells.

Download the program

‘Off-the-Shelf’ Immunotherapy Gets Special Treatment in Special Issue of The Journal Cells

Cellular immunotherapy is revolutionizing cancer treatment.  And off-the-shelf, or allogeneic, treatments are beginning to replace technologies developed individually for each patient.

This is good news because the potential of allogeneic therapies is great. They promise to significantly save time and cut costs compared to individualised, or autologous, treatments.

In Cells special issue ‘Allogeneic Cell Cancer Immunotherapies” editor Alan Trounson introduces five papers from leading research teams, including two from Cartherics’ scientists. They all tackle the major scientific hurdle the new technologies face: possible rejection of treatments by patients’ immune systems.

Trounson is impressed by the solutions presented. “Early progress is encouraging, but the outcome of human clinical trials remains essential to evaluate the safety and efficacy of these new allogeneic cell therapy approaches,” he notes.

The Special Issue is now available.

Download (pdf)

Presentation: The iPSC-Derived Cell Therapies Summit

Chief Scientific Officer, Dr Richard Boyd

Deriving “off-the-shelf” cancer fighting immune effector cells from iPSC offers a remarkable opportunity for overcoming the limitations of current autologous CAR-T cell therapies. However as promising as the iPSC approach is, it also presents a series of different challenges.

On 7 December 2021 Richard discussed the challenges and potential solutions. Among the solutions is Cartherics’ platform for creating clinic-ready, gene-edited, CAR-iNK cells for application in solid tumour immunotherapy.

View summit page

‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells

Cellular immunotherapy is revolutionizing cancer treatment. However, autologous transplants are complex, costly, and limited by the number and quality of T cells that can be isolated from and expanded for re-infusion into each patient.

This paper demonstrates a stromal support cell-free in vitro method for the differentiation of T cells from umbilical cord blood hematopoietic stem cells (HSCs).

https://www.mdpi.com/2073-4409/10/10/2631

Download (pdf)

Weaponising Cell Therapies To Fight Cancer – The Multi-Functional Cell Therapies Summit

From autologous cancer killers to off-the-shelf products targeting solid tumours like ovarian, prostate and breast cancer, Cartherics is developing them all.

The potential of such therapies is the reason Cartherics’ Chief Scientific Officer Richard Boyd was invited to speak at the international Multi-Functional Cell Therapies Summit in Boston, 4-6 May 2021.

In his presentation, Richard updated delegates on Cartherics’ recent advances.

Download (pdf)

Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy

Natural killer (NK) cells are potent innate immune system effector lymphocytes armed with multiple mechanisms for killing cancer cells. Given the dynamic roles of NK cells in tumor surveillance, they are fast becoming a next-generation tool for adoptive immunotherapy. Many strategies are being employed to increase their number and improve their ability to overcome cancer resistance and the immunosuppressive tumor microenvironment.

https://www.mdpi.com/2073-4409/10/5/1058

Download (pdf)

Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer

Chimeric antigen receptor (CAR) T cells have revolutionized blood cancer immunotherapy; however, their efficacy against solid tumors has been limited. A common mechanism of tumor escape from single target therapies is downregulation or mutational loss of the nominal epitope.

https://www.cell.com/molecular-therapy-family/oncolytics/fulltext/S2372-7705(21)00002-4

Download PDF

Targeting human ovarian cancer with immune cells derived from the patient or from homozygous hla haplotype ips cells

Chimeric antigen receptors (CARs) have been used for efficient destruction of B cell tumors but have been relatively ineffective as therapy for solid tumors. Ovarian cancer is a difficult cancer to treat, with five-year survival rates commonly around 25% of patients at diagnosis.
Abstract (pdf)

Off-the-shelf iPSC derived CAR-NK immunotherapy for solid tumors

Principal Scientist Dr Nicholas Boyd

The clinical impact of Chimeric Antigen Receptor T cell (CAR-T) technologies on hematological malignancies have revolutionized cancer treatment. 

However, current autologous CAR-T therapies face major roadblocks for mass adoption. 

Published (pdf)
Abstract (pdf)

iScience Review – Strategies for Genetically Engineering Hypoimmunogenic Universal Pluripotent Stem Cells

Despite progress in developing cell therapies, such as T cell or stemcell therapies to treat diseases, immunoincompatibility remains a major barrier to clinical application.

Given the fact that a host’s immune system may reject allogeneic transplanted cells, methods have been developed to genetically modify patients’primary cells.

Download (pdf)

Presentation: Cartherics on the Mesa

In October 2019 Cartherics attended the prestigious Cell & Gene Meeting on the Mesa https://www.meetingonthemesa.com/ in Carlsbad, California.

Cartherics Chief Scientific Officer, Richard Boyd, presented details to delegates of Cartherics’ pre-clinical in vitro and animal model research, cell manufacture for clinical trials, and corporate game plan.

Download (pdf)

Sign up for investor news and Cartherics updates

Latest News

3 Cheers for a Cartherics Board Member
General The Pipeline

3 Cheers for a Cartherics Board Member

June 16, 2022
Bryan Williams ranked among the world’s most prominent scientists By Leigh Dayton, 16 June 2022 Cartherics is delighted to announce...
She’s an Adventurer, Advocate, Author and a Cancer Survivor
General The Pipeline

She’s an Adventurer, Advocate, Author and a Cancer Survivor

June 9, 2022
Now Heather Hawkins is a member of the Cartherics Board By Leigh Dayton  9 June 2022 It’s official. As of...
Presentation at the Locust Walk Stem Cell Tx Conference
Conferences General

Presentation at the Locust Walk Stem Cell Tx Conference

April 8, 2022
Dr Ian Nisbet Chief Operating Officer Held in partnership with Harvard Stem Cell Institute, this virtual one-day investor and partner...

Latest video

https://youtu.be/WprTZ_scgNw

Contact Us

Address
12 Ferntree Place
Notting Hill VIC 3168
AUSTRALIA

Contact
+61 3 8572 2500
info@cartherics.com

Links

  • Home
  • Our Vision & Our Mission
  • Contact Us
  • Privacy Policy

Connect with us

Copyright ©     |   Cartherics Pty ltd
Go to Top